NCT05945498View on ClinicalTrials.gov

Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

May 10, 2023

Primary Completion Date

June 16, 2023

Study Completion Date

September 18, 2023

Conditions
Tuberculosis Infection
Interventions
BIOLOGICAL

TB/Flu-05E vaccine

Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the TB10.4 and HspX antigens of M. tuberculosis

BIOLOGICAL

Placebo

Participants will receive single intranasal injection of placebo buffer solution

Trial Locations (1)

Unknown

Smorodintsev Research Institute of Influenza, Saint Petersburg

All Listed Sponsors
lead

Tatyana Zubkova

OTHER

NCT05945498 - Evaluation of ТВ/Flu-05Е Vaccine for the Prevention of Tuberculosis Infection in BCG-vaccinated Volunteers Aged 18-50 Years | Biotech Hunter | Biotech Hunter